Jeremy Graff
Directeur Technique/Scientifique/R&D chez IMV INC.
Fortune : 5 413 $ au 31/05/2024
Profil
Jeremy R.
Graff is currently an Independent Director at IN8bio, Inc. since 2023 and the Chief Scientific Officer at IMV, Inc. since 2021.
Previously, he served as the President & Chief Scientific Officer at Biothera Pharmaceutical, Inc. from 2018 to 2020.
He also held positions as the Chief Development Officer & Senior VP-Research at Hibercell, Inc. and as the President & Chief Scientific Officer at Biothera, Inc. Dr. Graff obtained his undergraduate degree from Thomas More University and his doctorate from the University of Kentucky.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IN8BIO, INC.
0,01% | 12/06/2024 | 4 549 ( 0,01% ) | 5 413 $ | 31/05/2024 |
IMV INC.
-.--% | 20/03/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Postes actifs de Jeremy Graff
| Sociétés | Poste | Début |
|---|---|---|
| IMV INC. | Directeur Technique/Scientifique/R&D | 14/06/2021 |
| IN8BIO, INC. | Directeur/Membre du Conseil | 01/05/2023 |
Anciens postes connus de Jeremy Graff
| Sociétés | Poste | Fin |
|---|---|---|
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | President | 01/06/2020 |
Biothera Pharmaceutical, Inc.
 Biothera Pharmaceutical, Inc. Medical/Nursing ServicesHealth Services Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN. | President | 01/06/2020 |
Hibercell, Inc.
 Hibercell, Inc. Miscellaneous Commercial ServicesCommercial Services Hibercell, Inc. specializes on tumor dormancy detection and therapeutics. It provides treatment for primary tumors, metastatic cancer. The company was founded by Alan Rigby, Julio Aguirre-Ghiso, and Ari Nowacek and is headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | - |
Formation de Jeremy Graff
| University of Kentucky | Doctorate Degree |
| Thomas More University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMV INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Biothera, Inc.
Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Commercial Services |
Biothera Pharmaceutical, Inc.
Biothera Pharmaceutical, Inc. Medical/Nursing ServicesHealth Services Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN. | Health Services |
Hibercell, Inc.
Hibercell, Inc. Miscellaneous Commercial ServicesCommercial Services Hibercell, Inc. specializes on tumor dormancy detection and therapeutics. It provides treatment for primary tumors, metastatic cancer. The company was founded by Alan Rigby, Julio Aguirre-Ghiso, and Ari Nowacek and is headquartered in New York, NY. | Commercial Services |
